IJMPR 2025, 9(3), 43-47

International Journal of Modern Pharmaceutical Research

www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Review Article
SJIF Impact Factor: 6.669

"THE ROLE OF INTERMITTENT FASTING IN ENHANCING CHEMOTHERAPY OUTCOMES: A NARRATIVE REVIEW"

Afrin Shajahan MD* and Amal Abdul Hassan MBBS

India.

Article Received on: 29/12/2024

Article Revised on: 19/01/2025

Article Accepted on: 09/02/2025

***Corresponding Author**

Afrin Shajahan MD

India.

ABSTRACT

Cancer remains a leading motive of morbidity and mortality globally, with chemotherapy being a number one remedy modality. Despite its effectiveness in targeting malignant cells, chemotherapy regularly has intense consequences, toxicity to healthy tissues, and the improvement of drug resistance. In recent years, intermittent fasting (IF) has received interest as a capability method to beautify chemotherapy results whilst mitigating its destructive effects. IF affects diverse biological tactics, inclusive of metabolic reprogramming, oxidative strain discount, immune modulation, and autophagy activation. These mechanisms now not simplest boost the sensitivity of cancer cells to chemotherapeutic agents however additionally shield normal cells from remedy-associated harm. Additionally, IF may enhance affected person metabolic profiles and decrease systemic irritation, contributing to improved treatment tolerance and effects. This narrative review gives an in-intensity exploration of the current evidence at the position of IF in chemotherapy, examines the underlying organic mechanisms, and discusses capacity, clinical packages, obstacles, and future research directions.

KEYWORDS: Intermittent fasting, chemotherapy, most cancers treatment, metabolic modulation, oxidative strain, drug resistance, immune reaction, autophagy, treatment effects, most cancers therapy.

1. INTRODUCTION

Cancer continues to be a major public health challenge worldwide, with chemotherapy serving as a cornerstone treatment for various types of malignancies. While chemotherapy effectively targets rapidly dividing cancer cells, its use is often accompanied by severe adverse effects, including systemic toxicity, myelosuppression, gastrointestinal disturbances, and long-term complications such as secondary cancers and organ damage. Moreover, the emergence of chemotherapy resistance remains a formidable obstacle, diminishing treatment efficacy and compromising patient outcomes. These challenges underscore the urgent need for innovative approaches to improve chemotherapy responses and reduce associated toxicities.

Recent studies have highlighted intermittent fasting (IF)—a dietary intervention characterized by alternating periods of fasting and eating—as a promising strategy to enhance chemotherapy outcomes. IF exerts profound effects on cellular metabolism, stress resistance, and immune modulation. By inducing metabolic reprogramming, reducing oxidative damage, and promoting autophagy, IF creates a cellular environment that selectively sensitizes cancer cells to chemotherapy while safeguarding healthy cells. Additionally, IF may mitigate inflammation and improve metabolic health, contributing to better treatment tolerance and enhanced clinical outcomes.

This narrative review explores the existing evidence on the role of IF as an adjunct to chemotherapy. It delves into the biological mechanisms that underlie its potential benefits, evaluates clinical findings, and discusses practical implications and challenges for implementation. The review also highlights critical gaps in current knowledge and identifies key areas for future research to establish IF as a clinically viable approach in cancer therapy.

1.1 Biological Mechanisms of Intermittent Fasting in Chemotherapy

The potential therapeutic benefits of intermittent fasting (IF) in cancer treatment arise from its influence on multiple biological pathways, including metabolic reprogramming, stress resistance, immune system modulation, and autophagy induction. These mechanisms collectively enhance chemotherapy efficacy while reducing treatment-related toxicity.



1.1.1 Metabolic Reprogramming and Tumor Cell Sensitization: Cancer cells primarily rely on glycolysis for energy production, even in the presence of oxygen—a phenomenon known as the Warburg effect. IF induces metabolic shifts that create an energy-deprived environment, selectively sensitizing tumor cells to chemotherapy while preserving the viability of normal cells. Key metabolic changes associated with IF include.

- Reduced glucose and insulin levels: Limiting energy availability for cancer cells.
- Suppression of IGF-1 and mTOR pathways: Inhibiting cellular proliferation and promoting apoptosis in cancer cells.
- Increased ketogenesis: Elevating metabolic stress in cancer cells while supporting normal cell function through alternative energy sources.

1.1.2 Differential Stress Resistance (DSR) and Normal Cell Protection: Normal cells possess adaptive mechanisms to cope with stress, such as fasting-induced DNA repair activation and temporary suppression of proliferation. In contrast, cancer cells, due to their dysregulated metabolism and rapid, uncontrolled growth, lack the ability to activate these protective responses. This differential stress resistance makes cancer cells more susceptible to chemotherapy-induced cytotoxicity, sparing healthy cells from damage.

1.1.3 Immune System Modulation: Fasting plays a crucial role in modulating immune functions, thereby enhancing chemotherapy responses. The key immunological effects of IF include.

- Increased cytotoxic T-cell activity: Strengthening the immune system's ability to target and destroy cancer cells.
- Reduction in pro-inflammatory cytokines: Mitigating tumor-promoting inflammation in the tumor microenvironment.
- Enhanced immunogenic cell death (ICD): Improving the immune system's ability to recognize and attack cancer cells following chemotherapy.

1.1.4 Induction of Autophagy and Chemotherapy Potentiation: Autophagy, a process of cellular self-digestion, is activated by IF and plays a crucial role in maintaining cellular homeostasis. In the context of cancer therapy, autophagy provides multiple benefits

- Enhanced chemotherapy-induced apoptosis: Amplifying cancer cell death.
- Reduction in drug resistance: Limiting mechanisms that allow cancer cells to evade treatment.
- Improved tumor response: Boosting the overall effectiveness of chemotherapy.

These interconnected biological pathways highlight the potential of IF as a complementary strategy in chemotherapy, providing a foundation for further clinical exploration and application.

1.2 Clinical Evidence Supporting IF in Chemotherapy: Several preclinical and clinical studies have explored the potential of intermittent fasting (IF) as an adjunct to chemotherapy, demonstrating promising results in enhancing treatment efficacy and minimizing adverse effects.

1.2.1 Preclinical Studies: Animal model studies have provided strong evidence supporting the role of IF in improving chemotherapy outcomes. Key findings from these studies include.

- Increased tumor cell death: IF selectively sensitizes cancer cells to chemotherapy while preserving normal tissue integrity.
- Reduced chemotherapy-induced toxicity: Fasting cycles protect against common side effects such as neutropenia and gastrointestinal damage.
- Delayed tumor progression: IF in combination with chemotherapy has shown significant delays in tumor growth in models of breast, colon, and glioblastoma cancers.

  These preclinical results highlight the potential of IF to optimize chemotherapy efficacy and reduce treatment-related toxicity, laying the groundwork for clinical investigation.

1.2.2 Clinical Studies: Early-phase clinical trials have demonstrated encouraging outcomes for cancer patients incorporating IF during chemotherapy. Notable findings from these studies include.

- Reduced chemotherapy-related side effects: Patients practicing IF reported fewer instances of nausea, fatigue, and myelosuppression compared to those not fasting.
- Improved tumor response rates: Some studies observed enhanced tumor shrinkage and reduced chemotherapy resistance among fasting patients.
- Safety and tolerability: No significant adverse effects were reported among patients undergoing short-term fasting prior to chemotherapy, suggesting the feasibility of this approach.

  Despite these promising findings, the current body of clinical evidence is limited by small sample sizes and heterogeneity in fasting protocols. Large-scale randomized controlled trials (RCTs) are essential to validate these results and establish standardized, clinically safe fasting regimens that can be seamlessly integrated into oncology practice.

1.3 Potential Benefits of IF in Chemotherapy: Emerging evidence suggests that intermittent fasting (IF) may provide multiple advantages when integrated with chemotherapy, potentially improving both treatment outcomes and patient experiences. Key benefits include

1.3.1 Enhanced Tumor Sensitivity to Chemotherapy: The metabolic stress induced by fasting creates an energy-deprived environment that selectively makes cancer cells more vulnerable to chemotherapeutic agents. This increased sensitivity can enhance the cytotoxic effects of chemotherapy, improving overall treatment efficacy.

1.3.2 Reduced Chemotherapy Toxicity: In response to fasting, normal cells activate stress resistance pathways that protect them from the damaging effects of chemotherapy. This protective mechanism helps minimize common toxicities such as organ damage, myelosuppression, and gastrointestinal disturbances.

1.3.3 Improved Patient Tolerance: IF has been associated with a reduction in chemotherapy-related side effects, including fatigue, nausea, and immune suppression. By improving patients' metabolic profiles and reducing inflammation, IF may help enhance overall treatment tolerance and quality of life.

1.3.4 Potential Synergy with Other Therapies: IF may complement other cancer treatments, such as immunotherapy and targeted therapies, by enhancing their efficacy. Fasting-induced immune modulation and metabolic reprogramming may create a more favorable environment for these therapies to achieve optimal outcomes.

These potential benefits underscore the importance of further research to establish safe and effective fasting protocols and to fully integrate IF into personalized cancer care strategies.

2. Limitations and Challenges: While intermittent fasting (IF) holds significant promise as an adjunct to chemotherapy, several limitations and challenges need to be addressed before it can be widely adopted in clinical oncology.

- Lack of Standardized Protocols: There is currently no consensus on the optimal fasting duration, frequency, or regimen for cancer patients undergoing chemotherapy. The lack of standardized protocols makes it difficult to implement IF consistently in clinical practice.
- Variability in Patient Tolerance: Not all cancer patients are suitable candidates for IF. Individuals at risk of malnutrition, those with cachexia, or patients requiring continuous nutritional support may face difficulties adhering to fasting protocols. Personalized assessments are essential to ensure patient safety and tolerability.
- Limited Large-Scale Clinical Trials: Although early-phase clinical studies have shown promising results, robust evidence from large-scale randomized controlled trials (RCTs) is still lacking. Comprehensive research is needed to validate the safety, efficacy, and long-term outcomes of IF in diverse cancer populations.

  Addressing these challenges through continued research and clinical evaluation will be crucial in establishing IF as a viable and safe approach to enhance chemotherapy outcomes.



3. Future Directions: To successfully integrate intermittent fasting (IF) into clinical oncology, future research should prioritize key areas that address existing knowledge gaps and optimize its therapeutic potential.

- Randomized Controlled Trials (RCTs): Well-designed, large-scale RCTs are essential to identify the most effective fasting regimens, including the optimal duration, frequency, and timing of fasting in relation to chemotherapy cycles. These trials should also evaluate safety, adherence, and patient-reported outcomes.
- Long-Term Studies: Longitudinal studies are needed to assess the long-term impact of IF on survival rates, disease recurrence, and quality of life. Understanding the sustained effects of fasting on tumor progression and treatment outcomes will be critical for clinical adoption.
- Personalized Fasting Approaches: Future research should explore individualized fasting protocols tailored to tumor type, genetic mutations, metabolic status, and patient-specific health conditions. Personalized approaches will help maximize therapeutic benefits while minimizing risks.
- Combination Strategies: Investigating the synergy between IF and other cancer treatments, such as immunotherapy and targeted therapies, holds significant promise. Understanding how fasting-induced metabolic and immune changes interact with these therapies could unlock new avenues for combination treatment strategies.

  By addressing these research priorities, IF has the potential to become a transformative adjunct in oncology, improving chemotherapy outcomes and enhancing the overall patient experience.

4. CONCLUSION

Intermittent fasting (IF) is emerging as a promising, non-pharmacologic strategy to enhance the efficacy of chemotherapy while reducing its toxic side effects. By modulating metabolic and cellular processes, IF has the unique potential to selectively increase tumor cell sensitivity to chemotherapeutic agents while protecting healthy tissues from damage. This dual effect offers a compelling opportunity to improve treatment outcomes and patient well-being.

Despite its potential, further research is essential to establish standardized and clinically safe fasting protocols that can be seamlessly integrated into routine oncology practice. Robust clinical trials and long-term studies are needed to evaluate its efficacy across different cancer types, identify optimal fasting durations, and understand patient-specific factors that influence outcomes. If validated, IF could become a transformative adjunct to conventional cancer therapies, offering a simple and cost-effective approach to enhance chemotherapy effectiveness and improve patients' overall quality of life.

5. REFERENCES

1. Longo VD, Mattson MP. Fasting: Molecular mechanisms and clinical applications. Cell Metab., 2014; 19(2): 181-192.
2. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci USA., 2008; 105(24): 8215-8220.
3. Lee C, Raffaghello L, Longo VD. Starvation, detoxification, and cancer therapy. Drug Discov Today, 2012; 17(19-20): 1140-1147.
4. Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, et al. A periodic fasting-mimicking diet reduces age-related neuroinflammation to alleviate cognitive decline. Cell Rep., 2015; 22(10): 3972-3983.
5. Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell, 2014; 14(G): 810-823.
6. G. Caffa I, Spagnolo V, Vernieri C, Valdemarin F, Becherini P, Wei M, et al. Fasting-mimicking diet and hormone therapy induce breast cancer

regression. Nature, 2020; 583(7817): G20-G24.
7. Nencioni A, Caffa I, Cortellino S, Longo VD. Fasting and cancer: Molecular mechanisms and clinical application. Nat Rev Cancer, 2018; 18(11): 707-719.
8. Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell, 201G; 30(1): 147-1G0.
9. Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng CW, et al. Fasting-mimicking diet reduces chemotherapy-induced myelosuppression and potentiates doxorubicin antitumor efficacy. Cancer Cell, 201G; 30(1): 171-185.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell, 2011; 144(5): G4G-G74.
11. Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: Implications for novel therapeutics. Carcinogenesis, 2014; 35(3): 515-527.
12. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest, 2013; 123(3): 980-989.
13. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the G5 and younger but not older population. Cell Metab, 2014; 19(3): 407-417.
14. Morscher RJ, Droll A, Hiller K, Malli R, Graier WF, Kofler B. Ketone body metabolism in glioblastoma. Clin Cancer Res., 2019; 25(18): 5403-5413.
15. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab, 2017; 25(2): 2G2-284.
16. 1G. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell, 2011; 14G(5): G82-G95.
17. Rangan P, Choi I, Wei M, Navarrete G, Guen E, Brandhorst S, et al. Fasting-mimicking diet slows neurodegeneration and improves cognitive performance. Cell Rep., 2019; 27(7): 20G3-2077.
18. Vernieri C, Fucà G, Ligorio F, Huber V, Vingiani A, Iannelli F, et al. Fasting-mimicking diet is safe and reshapes metabolism and anticancer immunity in patients with cancer. Cancer Discov., 2022; 12(1): 90-107.
19. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY), 2009; 1(12): 988-1007.
20. Brandhorst S, Wei M, Hwang S, Morgan TE, Longo VD. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol, 2013; 48(10): 1120-1128.
21. Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M. Starvation-induced stress response blocks radiation-induced DNA damage repair. Oncogene, 2012; 31(13): 1G09-1G20.
22. De Groot S, Pijl H, van der Hoeven JJM, Kroep JR. Effects of short-term fasting on cancer treatment. J Exp Clin Cancer Res., 2019; 38(1): 209.
23. Hofer SJ, Davinelli S, Bergmann M, Scapagnini G, Madeo F. Caloric restriction mimetics in nutrition and clinical trials. Front Nutr., 2021; 8: 717343.
24. Patterson RE, Sears DD. Metabolic effects of intermittent fasting. Annu Rev Nutr., 2017; 37: 371-393.
25. Hine C, Harputlugil E, Zhang Y, Ruckenstuhl C, Lee BC, Brace L, et al. Endogenous hydrogen sulfide production is essential for dietary restriction benefits. Cell, 2015; 1G0(1-2): 132-144.
26. 2G. Antunes F, Erustes AG, Costa AJ, Nascimento NO, Bincoletto C, Ureshino RP, et al. Autophagy and intermittent fasting: The connection for cancer therapy? Clin Sci (Lond), 2018; 132(11): 1197-1219.